(VBK) VERBIO Vereinigte BioEnergie - Overview
Stock: Biodiesel, Bioethanol, Biomethane, Glycerine, Animal Feed
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 60.9% |
| Relative Tail Risk | -9.14% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.80 |
| Alpha | 146.81 |
| Character TTM | |
|---|---|
| Beta | 0.460 |
| Beta Downside | 0.739 |
| Drawdowns 3y | |
|---|---|
| Max DD | 84.35% |
| CAGR/Max DD | -0.26 |
Description: VBK VERBIO Vereinigte BioEnergie December 25, 2025
Verbio SE (XETRA:VBK) is a German-based producer and distributor of bio-fuels and renewable chemicals, operating across Biodiesel, Bioethanol/Biomethane, and ancillary “Other” segments. Its product portfolio spans biodiesel, bioethanol, biomethane, pharma-grade glycerine, olefin metathesis catalysts, animal-feed additives (Verbio Proti Flow, Verbio Grain Pro), phytosterols (Sterocellent), and fertilizers, plus related trading, transport and logistics services. Customers include oil mills, pharma firms, logistics operators, fleet managers, utilities, farmers, and LNG/CNG stations.
Key operational metrics (FY 2023) show a production capacity of roughly 1.5 Mt yr⁻¹ of biodiesel and 0.5 Mt yr⁻¹ of bioethanol, with EBITDA margin hovering near 6 % after a 2022-23 cost-inflation adjustment. The firm’s earnings are highly sensitive to EU Renewable Energy Directive (RED II) credit prices and feedstock costs, while the growing demand for renewable diesel under the EU’s 2025 fuel-mix mandates provides a secular upside. In North America, Verbio’s biomethane joint venture contributes ~15 % of total revenue and benefits from federal tax credits for renewable natural gas.
For a deeper, data-driven valuation you may want to explore Verbio’s metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: -119.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.09 > 0.02 and ΔFCF/TA -4.51 > 1.0 |
| NWC/Revenue: 14.71% < 20% (prev 21.16%; Δ -6.45% < -1%) |
| CFO/TA 0.00 > 3% & CFO 2.69m > Net Income -119.1m |
| Net Debt (244.8m) to EBITDA (37.5m): 6.53 < 3 |
| Current Ratio: 1.78 > 1.5 & < 3 |
| Outstanding Shares: last quarter (67.4m) vs 12m ago 5.03% < -2% |
| Gross Margin: 6.49% > 18% (prev 0.16%; Δ 632.3% > 0.5%) |
| Asset Turnover: 125.5% > 50% (prev 112.4%; Δ 13.12% > 0%) |
| Interest Coverage Ratio: -5.67 > 6 (EBITDA TTM 37.5m / Interest Expense TTM 16.8m) |
Altman Z'' 1.71
| A: 0.19 (Total Current Assets 556.2m - Total Current Liabilities 312.1m) / Total Assets 1.28b |
| B: 0.15 (Retained Earnings 193.6m / Total Assets 1.28b) |
| C: -0.07 (EBIT TTM -95.2m / Avg Total Assets 1.32b) |
| D: 0.44 (Book Value of Equity 235.1m / Total Liabilities 540.2m) |
| Altman-Z'' Score: 1.71 = BBB |
Beneish M -2.06
| DSRI: 1.13 (Receivables 105.9m/86.3m, Revenue 1.66b/1.53b) |
| GMI: 2.53 (GM 6.49% / 16.40%) |
| AQI: 0.17 (AQ_t 0.00 / AQ_t-1 0.03) |
| SGI: 1.08 (Revenue 1.66b / 1.53b) |
| TATA: -0.09 (NI -119.1m - CFO 2.69m) / TA 1.28b) |
| Beneish M-Score: -2.06 (Cap -4..+1) = BB |
What is the price of VBK shares?
Over the past week, the price has changed by -6.26%, over one month by +0.17%, over three months by +46.12% and over the past year by +145.59%.
Is VBK a buy, sell or hold?
What are the forecasts/targets for the VBK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14.7 | -37.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 24.8 | 6.1% |
VBK Fundamental Data Overview February 02, 2026
P/S = 0.9526
P/B = 2.1022
Revenue TTM = 1.66b EUR
EBIT TTM = -95.2m EUR
EBITDA TTM = 37.5m EUR
Long Term Debt = 173.4m EUR (from longTermDebt, last quarter)
Short Term Debt = 103.8m EUR (from shortTermDebt, last quarter)
Debt = 296.9m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 244.8m EUR (from netDebt column, last quarter)
Enterprise Value = 1.36b EUR (1.12b + Debt 296.9m - CCE 52.2m)
Interest Coverage Ratio = -5.67 (Ebit TTM -95.2m / Interest Expense TTM 16.8m)
EV/FCF = -11.62x (Enterprise Value 1.36b / FCF TTM -117.0m)
FCF Yield = -8.61% (FCF TTM -117.0m / Enterprise Value 1.36b)
FCF Margin = -7.05% (FCF TTM -117.0m / Revenue TTM 1.66b)
Net Margin = -7.18% (Net Income TTM -119.1m / Revenue TTM 1.66b)
Gross Margin = 6.49% ((Revenue TTM 1.66b - Cost of Revenue TTM 1.55b) / Revenue TTM)
Gross Margin QoQ = 13.21% (prev -16.38%)
Tobins Q-Ratio = 1.06 (Enterprise Value 1.36b / Total Assets 1.28b)
Interest Expense / Debt = 0.82% (Interest Expense 2.44m / Debt 296.9m)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -71.4m (EBIT -95.2m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 1.78 (Total Current Assets 556.2m / Total Current Liabilities 312.1m)
Debt / Equity = 0.40 (Debt 296.9m / totalStockholderEquity, last quarter 743.2m)
Debt / EBITDA = 6.53 (Net Debt 244.8m / EBITDA 37.5m)
Debt / FCF = -2.09 (negative FCF - burning cash) (Net Debt 244.8m / FCF TTM -117.0m)
Total Stockholder Equity = 815.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -9.01% (Net Income -119.1m / Total Assets 1.28b)
RoE = -14.60% (Net Income TTM -119.1m / Total Stockholder Equity 815.7m)
RoCE = -9.62% (EBIT -95.2m / Capital Employed (Equity 815.7m + L.T.Debt 173.4m))
RoIC = -6.77% (negative operating profit) (NOPAT -71.4m / Invested Capital 1.05b)
WACC = 6.14% (E(1.12b)/V(1.41b) * Re(7.61%) + D(296.9m)/V(1.41b) * Rd(0.82%) * (1-Tc(0.25)))
Discount Rate = 7.61% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -8.46%
Fair Price DCF = unknown (Cash Flow -117.0m)
EPS Correlation: -87.58 | EPS CAGR: -17.58% | SUE: -0.10 | # QB: 0
Revenue Correlation: -58.37 | Revenue CAGR: -1.21% | SUE: 1.76 | # QB: 1
EPS current Year (2026-06-30): EPS=0.07 | Chg30d=+0.027 | Revisions Net=-1 | Growth EPS=+103.2% | Growth Revenue=+11.2%
EPS next Year (2027-06-30): EPS=0.74 | Chg30d=-0.052 | Revisions Net=-3 | Growth EPS=+969.0% | Growth Revenue=+13.0%